Scarica l'app Stockscreener
12.71
3.58%
0.4305
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study - Insider Monkey
Fulcrum Therapeutics (FULC) Price Target Increased by 32.56% to 19.38 - Nasdaq
How Fulcrum Therapeutics Inc. stock performs in stagflationWeekly Trade Summary & Low Volatility Stock Suggestions - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc stock is a must watch in 20252025 Investor Takeaways & High Yield Stock Recommendations - moha.gov.vn
What makes Fulcrum Therapeutics Inc. stock attractive to growth fundsJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Why Fulcrum Therapeutics Inc. stock is considered a top pick2025 Retail Activity & Free Technical Pattern Based Buy Signals - Улправда
Is Fulcrum Therapeutics Inc. stock undervalued vs historical averages2025 Performance Recap & Community Driven Trade Alerts - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc. stock is a must watch in 2025 - ulpravda.ru
Is Fulcrum Therapeutics Inc. stock supported by strong cash flows - ulpravda.ru
Published on: 2025-12-19 18:03:13 - DonanımHaber
Can Fulcrum Therapeutics Inc. stock deliver consistent earnings growthQuarterly Performance Summary & High Win Rate Trade Tips - DonanımHaber
Why Fulcrum Therapeutics Inc. stock is a must watch in 20252025 Dividend Review & Low Risk Investment Opportunities - Улправда
Can Fulcrum Therapeutics Inc. stock surprise with earnings upsideTrade Signal Summary & Technical Confirmation Trade Alerts - DonanımHaber
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterJuly 2025 Sector Moves & Real-Time Volume Triggers - DonanımHaber
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Market Trends: Will Fulcrum Therapeutics Inc. stock attract more institutional investorsWeekly Investment Report & Technical Entry and Exit Tips - Улправда
Insider Sell: Curtis Oltmans Sells Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% on Insider Selling - Defense World
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - ca.investing.com
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com Nigeria
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
Owner RA Capital Management LP Sells 4,175,139 ($58.4M) Of Fulcrum Therapeutics Inc [FULC] - TradingView — Track All Markets
Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Expands Offering to $175M - GuruFocus
Fulcrum Therapeutics stock falls after pricing $175 million public offering By Investing.com - Investing.com Canada
Fulcrum Therapeutics prices $175 million public offering By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Prices $175 Million Stock Offering - marketscreener.com
Fulcrum Therapeutics prices $175 million public offering - Investing.com
What is HC Wainwright's Forecast for FULC FY2028 Earnings? - MarketBeat
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Fulcrum Therapeutics announces pricing of upsized $175.0 million public offering of common stock and pre-funded warrants - marketscreener.com
Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
B of A Securities Maintains Fulcrum Therapeutics (FULC) Underperform Recommendation - Nasdaq
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
FULC: Analyst Rating Maintained by B of A Securities, Price Targ - GuruFocus
Bank of America Forecasts Strong Price Appreciation for Fulcrum Therapeutics (NASDAQ:FULC) Stock - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.8% on Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Yahoo Finance
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial - MSN
Fulcrum Therapeutics dips after unveiling $150 million share sale - TradingView — Track All Markets
Owner RA Capital Healthcare Fund LP Files To Sell 4,175,139 Of Fulcrum Therapeutics Inc [FULC] - TradingView — Track All Markets
RBC Capital Maintains Fulcrum Therapeutics (FULC) Sector Perform Recommendation - Nasdaq
Fulcrum Therapeutics (FULC) Launches $150M Public Stock Offering - GuruFocus
Fulcrum stock drops after announcing $150 million public offering By Investing.com - Investing.com Australia
Fulcrum Therapeutics launches $150 million common stock offering - Investing.com
Fulcrum stock drops after announcing $150 million public offering - Investing.com
0.21%
2.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):